Lymphadenectomy for Pancreatic Head Cancer: Standard or Extended?
Primary Purpose
Pancreatic Ductal Adenocarcinoma
Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Pancreaticoduodenectomy with Standard lymphadenectomy
Pancreaticoduodenectomy with Extended lymphadenectomy
Sponsored by
About this trial
This is an interventional treatment trial for Pancreatic Ductal Adenocarcinoma focused on measuring Standard lymphadenectomy, extended lymphadenectomy, pancreaticoduodenectomy
Eligibility Criteria
Inclusion Criteria:
- Pathologic diagnosis of pancreatic ductal adenocarcinoma
- Signed the informed consents
Exclusion Criteria:
- Pathologic diagnosis of other pancreatic cancers
- Pre-operative anti-cancer treatment
- Recurrence patients
- Patients with contraindication(hepatic/ respiratory/ renal dysfunction, etc )
- Pre operative exam: Total bilirubin more than 250µmol/L
- AJCC stage IV
- Operation non radical
Sites / Locations
- Shanghai Ruijin Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Standard resection
Extended resection
Arm Description
Pancreaticoduodenectomy (child's digestive reconstruction); Standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b
Pancreaticoduodenectomy (child's digestive reconstruction)extended lymphadenectomy No8p 12a 12p 14c 14d 16
Outcomes
Primary Outcome Measures
All-cause mortality
Secondary Outcome Measures
all-cause mortality
Full Information
NCT ID
NCT02787187
First Posted
May 23, 2016
Last Updated
November 22, 2021
Sponsor
Ruijin Hospital
Collaborators
Shanghai Zhongshan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
1. Study Identification
Unique Protocol Identification Number
NCT02787187
Brief Title
Lymphadenectomy for Pancreatic Head Cancer: Standard or Extended?
Official Title
A Prospective Randomized Controlled Study Comparing Standard and Extended Lymphadenectomy for Pancreatic Head Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
November 2021
Overall Recruitment Status
Completed
Study Start Date
July 1, 2016 (Actual)
Primary Completion Date
October 2021 (Actual)
Study Completion Date
October 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ruijin Hospital
Collaborators
Shanghai Zhongshan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to compare outcomes of patients undergoing standard or extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatic Ductal Adenocarcinoma
Keywords
Standard lymphadenectomy, extended lymphadenectomy, pancreaticoduodenectomy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
230 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Standard resection
Arm Type
Active Comparator
Arm Description
Pancreaticoduodenectomy (child's digestive reconstruction); Standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b
Arm Title
Extended resection
Arm Type
Experimental
Arm Description
Pancreaticoduodenectomy (child's digestive reconstruction)extended lymphadenectomy No8p 12a 12p 14c 14d 16
Intervention Type
Procedure
Intervention Name(s)
Pancreaticoduodenectomy with Standard lymphadenectomy
Intervention Description
Pancreaticoduodenectomy:child's digestive reconstruction standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b
Intervention Type
Procedure
Intervention Name(s)
Pancreaticoduodenectomy with Extended lymphadenectomy
Intervention Description
Pancreaticoduodenectomy:child's digestive reconstruction extended lymphadenectomy: No8p 12a 12p 14c 14d 16
Primary Outcome Measure Information:
Title
All-cause mortality
Time Frame
3yrs post-operation
Secondary Outcome Measure Information:
Title
all-cause mortality
Time Frame
1yr post-operation
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Pathologic diagnosis of pancreatic ductal adenocarcinoma
Signed the informed consents
Exclusion Criteria:
Pathologic diagnosis of other pancreatic cancers
Pre-operative anti-cancer treatment
Recurrence patients
Patients with contraindication(hepatic/ respiratory/ renal dysfunction, etc )
Pre operative exam: Total bilirubin more than 250µmol/L
AJCC stage IV
Operation non radical
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Baiyong SHEN
Organizational Affiliation
Shanghai Ruijin Pancreatic Disease Center
Official's Role
Study Director
Facility Information:
Facility Name
Shanghai Ruijin Hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200032
Country
China
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Lymphadenectomy for Pancreatic Head Cancer: Standard or Extended?
We'll reach out to this number within 24 hrs